Your browser doesn't support javascript.
loading
The Dynamics of Nucleotide Variants in the Progression from Low-Intermediate Myeloma Precursor Conditions to Multiple Myeloma: Studying Serial Samples with a Targeted Sequencing Approach.
Oben, Bénedith; Cosemans, Charlotte; Geerdens, Ellen; Linsen, Loes; Vanhees, Kimberly; Maes, Brigitte; Theunissen, Koen; Cruys, Bert; Lionetti, Marta; Arijs, Ingrid; Bolli, Niccolò; Froyen, Guy; Rummens, Jean-Luc.
Afiliación
  • Oben B; Laboratory Experimental Hematology, Department Clinical Biology, Jessa Hospital, 3500 Hasselt, Belgium.
  • Cosemans C; Faculty of Medicine and Life Sciences, Hasselt University, 3500 Hasselt, Belgium.
  • Geerdens E; Laboratory Experimental Hematology, Department Clinical Biology, Jessa Hospital, 3500 Hasselt, Belgium.
  • Linsen L; Faculty of Medicine and Life Sciences, Hasselt University, 3500 Hasselt, Belgium.
  • Vanhees K; Centre for Environmental Sciences, Hasselt University, 3590 Diepenbeek, Belgium.
  • Maes B; Laboratory Molecular Diagnostics, Department Clinical Biology, Jessa Hospital, 3500 Hasselt, Belgium.
  • Theunissen K; Laboratory Experimental Hematology, Department Clinical Biology, Jessa Hospital, 3500 Hasselt, Belgium.
  • Cruys B; Activity Center Biobanking, University Hospitals Leuven, 3000 Leuven, Belgium.
  • Lionetti M; University Biobank Limburg (UBiLim), Clinical Biobank, Jessa Hospital, 3500 Hasselt, Belgium.
  • Arijs I; Faculty of Medicine and Life Sciences, Hasselt University, 3500 Hasselt, Belgium.
  • Bolli N; University Biobank Limburg (UBiLim), Clinical Biobank, Jessa Hospital, 3500 Hasselt, Belgium.
  • Froyen G; Laboratory Molecular Diagnostics, Department Clinical Biology, Jessa Hospital, 3500 Hasselt, Belgium.
  • Rummens JL; Department Hematology, Jessa Hospital, 3500 Hasselt, Belgium.
Cancers (Basel) ; 14(4)2022 Feb 18.
Article en En | MEDLINE | ID: mdl-35205782
ABSTRACT
Multiple myeloma (MM), or Kahler's disease, is an incurable plasma cell (PC) cancer in the bone marrow (BM). This malignancy is preceded by one or more asymptomatic precursor conditions, monoclonal gammopathy of undetermined significance (MGUS) and/or smoldering multiple myeloma (SMM). The molecular mechanisms and exact cause of this progression are still not completely understood. In this study, the mutational profile underlying the progression from low-intermediate risk myeloma precursor conditions to MM was studied in serial BM smears. A custom capture-based sequencing platform was developed, including 81 myeloma-related genes. The clonal evolution of single nucleotide variants and short insertions and deletions was studied in serial BM smears from 21 progressed precursor patients with a median time of progression of six years. From the 21 patients, four patients had no variation in one of the 81 studied genes. Interestingly, in 16 of the 17 other patients, at least one variant present in MM was also detected in its precursor BM, even years before progression. Here, the variants were present in the pre-stage at a median of 62 months before progression to MM. Studying these paired BM samples contributes to the knowledge of the evolutionary genetic landscape and provides additional insight into the mutational behavior of mutant clones over time throughout progression.
Palabras clave

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article

Texto completo: 1 Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2022 Tipo del documento: Article